LYEL's logo.
Ticker Symbol: LYEL

Lyell Immunopharma Inc

$10.94 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Currency: USD Asset Type: Common Stock CIK:0001806952

Company Profile

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: lyell.com
CEO: N/A
Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.44
Change: $0.01 ( 0.70%)
Days Range: $1.35 - $1.59
Beta: 1.70
52wk. High: $6.61
52wk. Low: $1.32
Ytd. Change -58.09%
50 Day Moving Average: $1.64
200 Day Moving Average: $2.46
Shares Outstanding: 251026997

Valuation

Market Cap: 36.1B
PE Ratio: -1.71
EPS (TTM): -0.84

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A